Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report

Comments
Loading...
  • Japan's health ministry panel authorized a plan to approve Novavax Inc's NVAX COVID-19 vaccine, which is set to be the fourth such vaccine to be approved in Japan.
  • It will be available for first and second shots with an interval of three weeks.
  • The Novavax product is a recombinant protein vaccine that uses parts of coronavirus protein. 
  • Related: Early Data Shows Novavax's COVID-19 Vaccine Triggers Immune Response To Omicron.
  • The vaccine's mechanism is different from the three already-approved ones in Japan - Pfizer Inc PFE / BioNTech SE BNTX, Moderna Inc MRNA, and AstraZeneca plc's AZN
  • The Novavax vials can be refrigerated at a temperature of 2 to 8 degrees Celsius, making them easy to transport and manage.
  • Also Read: Novavax's COVID-19 Shot Inches Up To FDA Authorization.
  • Takeda Pharmaceutical Co Ltd TAK is responsible for the Novavax vaccine's distribution in Japan. 
  • The Japanese government has concluded a contract with Takeda on the supply of 150 million vaccine doses in 2022.
  • Price Action: NVAX shares are down 5.84% at $55.15 on the last check Monday.
  • Photo by Daniel Schludi on Unsplash
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!